Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View

Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View

The increased use of newer potent immunomodulatory therapies for multiple sclerosis (MS), including natalizumab, fingolimod, and dimethyl fumarate, has expanded the patient population at risk for developing progressive multifocal leukoencephalopathy (PML). These MS therapies shift the profile of lym...

Full description

Bibliographic Details
Main Authors:	Elizabeth A. Mills, Yang Mao-Draayer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-02-01
Series:	Frontiers in Immunology
Subjects:	John Cunningham virus natalizumab fingolimod dimethyl fumarate glia
Online Access:	http://journal.frontiersin.org/article/10.3389/fimmu.2018.00138/full

Similar Items

USE OF DIMETHYL FUMARATE IN THE TREATMENT OF MULTIPLE SCLEROSIS: CLINICAL AND ECONOMIC ANALYSIS
by: V. R. Mkrtchyan, et al.
Published: (2016-12-01)

Therapeutic Value of Single Nucleotide Polymorphisms on the Efficacy of New Therapies in Patients with Multiple Sclerosis
by: María José Zarzuelo Romero, et al.
Published: (2021-04-01)

Progressive Multifocal Leukoencephalopathy Associated to Multiple Sclerosis Therapies: Review of the literature
by: Ana-Maria Vladila, et al.
Published: (2015-12-01)

Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients
by: Jan W. Traub, et al.
Published: (2019-11-01)

Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
by: Carla Prezioso, et al.
Published: (2022-01-01)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
by: Roberto De Masi, et al.
Published: (2021-01-01)

Multiple Sclerosis Treatment and Melanoma Development
by: Maria Luigia Carbone, et al.
Published: (2020-04-01)

Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series
by: Silvia Delgado, et al.
Published: (2021-02-01)

Progressive multifocal leukoencephalopathy in an HIV patient: A case report and literature review
by: Ting Lei, et al.
Published: (2023-08-01)

A rare case of progressive multifocal leukoencephalopathy – As a presenting manifestation of AIDS
by: S Sumangala, et al.
Published: (2020-01-01)

Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis
by: Jacqueline A. Nicholas, et al.
Published: (2020-07-01)

Fingolimod Augments Monomethylfumarate Killing of GBM Cells
by: Paul Dent, et al.
Published: (2020-01-01)

Corrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM Cells
by: Paul Dent, et al.
Published: (2020-04-01)

Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System
by: Kim M. A. De Kleijn, et al.
Published: (2020-06-01)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
by: Aliya Jaber, et al.
Published: (2023-02-01)

Thinking Outside the Ischemia Box: Advancements in the Use of Multiple Sclerosis Drugs in Ischemic Stroke
by: Athina-Maria Aloizou, et al.
Published: (2021-02-01)

A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus
by: Pristya Ramadhani, et al.
Published: (2018-06-01)

Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION―A 2-Year, Multicenter, Observational, Cohort Study
by: Helmut Butzkueven, et al.
Published: (2022-02-01)

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
by: Marco Iannetta, et al.
Published: (2022-01-01)

Assessment of Total Side Effects of Oral Agents for the Treatment of Relapsing–Remitting Multiple Sclerosis Patients in Imam Khomeini Clinic in Hamadan
by: M Ghiasian, et al.
Published: (2023-12-01)

Lipid-specific IgMs induce antiviral responses in the CNS: implications for progressive multifocal leukoencephalopathy in multiple sclerosis
by: Lorna Hayden, et al.
Published: (2020-08-01)

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis
by: Yara Dadalti Fragoso, et al.
Published: (2016-08-01)

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab
by: Florian Ottenlinger, et al.
Published: (2016-11-01)

Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisions
by: Elena Augusta Vola, et al.
Published: (2021-04-01)

Patients’ satisfaction with and views about treatment with disease-modifying drugs in multiple sclerosis
by: Caroline Vieira Spessotto, et al.
Published: (2016-08-01)

Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment
by: Carla Prezioso, et al.
Published: (2021-08-01)

Progressive multifocal leukoencephalopathy as a complication of disease-modifying treatment of multiple sclerosis
by: Maria N. Zakharova, et al.
Published: (2018-12-01)

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
by: Lilyana Amezcua, et al.
Published: (2023-04-01)

Progressive multifocal leukoencephalopathy triggered by COVID-19 in a previously asymptomatic person living with undiagnosed HIV infection
by: Yago Marcos Pessoa-Gonçalves, et al.
Published: (2023-12-01)

Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review
by: Anna Fournier, et al.
Published: (2017-05-01)

Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy (PML).
by: Hans eLindå, et al.
Published: (2013-02-01)

Therapeutic Potential of Fingolimod and Dimethyl Fumarate in Non-Small Cell Lung Cancer Preclinical Models
by: Tristan Rupp, et al.
Published: (2022-07-01)

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: risk reduction, management and possibilities for subsequent immunoregulation
by: Natalia V. Khachanova, et al.
Published: (2019-12-01)

Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature
by: Yinan Zhang, et al.
Published: (2018-07-01)

Germline Genetic Risk Variants for Progressive Multifocal Leukoencephalopathy
by: Peggy S. Eis, et al.
Published: (2020-03-01)

Is There a (Host) Genetic Predisposition to Progressive Multifocal Leukoencephalopathy?
by: Eli eHatchwell
Published: (2015-05-01)

Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients
by: Jan Traub, et al.
Published: (2020-07-01)

Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
by: Eli Hatchwell, et al.
Published: (2022-12-01)

Commentary: Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies
by: Joseph R. Berger, et al.
Published: (2023-03-01)

Dimethyl fumarate reduces inflammation in chronic active multiple sclerosis lesions
by: Zinger, Nicole, et al.
Published: (2023)